We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
04 May 2021 - 07 May 2021
Virtual Venue

Calcitonin and Procalcitonin Immunoassays Investigated for Medullary Thyroid Carcinoma

By LabMedica International staff writers
Posted on 23 Mar 2021
Print article
Image: Elecsys BRAHMS PCT Assay measures procalcitonin in human serum (Photo courtesy of Roche Diagnostics).
Image: Elecsys BRAHMS PCT Assay measures procalcitonin in human serum (Photo courtesy of Roche Diagnostics).
Medullary thyroid carcinoma (MTC) is caused by a malignant transformation in the parafollicular C-cells of the thyroid, where calcitonin (CT) is released. Nowadays, CT is the main tumor marker used in the diagnosis and follow-up of MTC patients.

However, CT assays suffer pre-analytic and analytic drawbacks: CT is prone to relatively rapid in vitro degradation by serum proteases which makes rapid processing of samples mandatory; and the presence of various different immunoreactive isoforms and fragments, which can lead to inaccurate results (usually false low) as well as poor comparability of results obtained by different assays.

Medical Scientists from the Institute of Oncology Research (Bellinzona, Switzerland) collected serum samples from 16 patients with active (i.e. primary tumor before surgery or post-surgical recurrent disease) and 23 with inactive (i.e. complete remission) MTC, 125 patients with non-MTC benign thyroid disease and 62 patients with non-MTC thyroid cancers, respectively.

The team performed simultaneously measurements using the Elecsys CT and Procalcitonin (PCT) assays that were accomplished on the fully automated Cobas e601 platform (Roche Diagnostics, Rotkreutz, Switzerland). The commercial PCT assays used was the BRAHMS GmbH (Henningdorf, Germany). The Elecsys BRAHMS procalcitonin assay was standardized against BRAHMS PCT luminescent immunoassay (LIA). Analytical (AS) and functional (FS) sensitivity values are 0.02 ng/mL and 0.06 ng/mL, respectively.

The team reported that both CT and PCT median values in active MTC (94 pmol/L and 1.17 ng/mL, respectively) were significantly higher compared with inactive MTC (0.28 and 0.06) and either benign (0.37 and 0.06) or malignant (0.28 and 0.06) non-MTC. Undetectable PCT was found in five non-MTC patients with false positive CT results. In addition, higher CT levels were found in patients with non-MTC benign disease compared to both inactive MTC and non-malignant MTC, respectively.

The authors concluded that the Elecsys PCT assay is a highly sensitive and specific alternative MTC marker. At the very least it appears useful in patients with positive CT results as negative PCT values securely exclude active MTC. The availability of both markers on the same automated platform facilitates reflex or reflective strategies to refine the laboratory diagnosis. The study was published in the March, 2021 issue of the journal Clinical Chemistry and Laboratory Medicine.

Related Links:
Institute of Oncology Research
Roche Diagnostics
BRAHMS GmbH


Gold Supplier
Clinical Chemistry Series
Clinical Chemistry Series
New
Gold Supplier
SARS-CoV-2 Antibody Test
SARS-CoV-2 UTAB FS
New
COVID-19 ELISA Test
Kantaro COVID-SeroKlir
New
SARS-CoV-2 Recombinant Antigens
SARS-CoV-2 Recombinant Antigens

Print article
BIOHIT  Healthcare OY

Channels

Molecular Diagnostics

view channel
Image: The EZ DNA Methylation-Direct Kit (Photo courtesy of Zymo Research)

Leukocyte Epigenomics and Artificial Intelligence Predict Late-Onset Alzheimer’s Disease

Alzheimer’s Disease (AD) is the most common form of age-related dementia, accounting for 60%–80% of such cases. The disorder causes a wide range of significant mental and physical disabilities, with profound... Read more

Industry

view channel
Image: The Novodiag platform combines real-time PCR and microarray capabilities to provide high-level multiplexing (Photo courtesy of Mobidiag Ltd.)

Hologic to Acquire Mobidiag to Strengthen Diagnostic Testing Business

Hologic, Inc. (Marlborough, MA, USA) has signed a definitive agreement to acquire Mobidiag Ltd. (Espoo, Finland) in a USD 795 million transaction that will accelerate the global growth of Mobidiag’s differentiated... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.